( her vital organs that can ultimatelyle...)Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data,Health

Study details

This trial was a randomized, double-blind, multicenter study that compared the efficacy and safety of two doses of Exforge in patients with high blood pressure who had not reached goals with a single medicine. A total of 894 patients, of whom 145 (16%) had type 2 diabetes, were randomized to either Exforge (valsartan/amlodipine) 160/5 mg (n=443) or Exforge 160/10 mg (n=451). The majority of patients had previously taken either a calcium channel blocker (CCB), angiotensin receptor blocker (ARB), angiotensin-converting enzyme inhibitor (ACE), beta blocker or diuretic. The primary endpoint measured the proportion of patients after eight and 16 weeks who reached the recommended treatment goals of blood pressure of <140/90 mmHg or a more aggressive goal of <130/80 mmHg.

Disclaimer

The foregoing release contains forward-looking statements which can be identified by the use of terminology such as, "can", "planned", "expected", or similar expressions, or by express or implied discussions regarding potential future revenue from Exforge. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Exforge will reach any particular sales levels. In particular, management's expectations regarding Exforge could be affected by, among other things, our ability
'"/>




Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
2. Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine